Quick Answer
BIOREGENX, INC. reported Total Revenue of $2.34 million for fiscal year 2024.
BIOREGENX, INC. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Total Revenue | $2.34M -31.4% |
$3.41M +7991.8% |
$42.2K -78.8% |
$198.6K | — |
| Net Income | -$23.05M -540.4% |
-$3.60M -4497.3% |
-$78.3K +19.2% |
-$96.9K | — |
| Diluted EPS | -$0.02 -100.0% |
-$0.01 | $0.00 | $0.00 | — |
| Total Assets | $508.5K -41.3% |
$865.8K +1363.7% |
$59.1K -53.7% |
$127.8K | — |
| Cash and Equivalents | $58.4K -53.4% |
$125.4K | — | — | — |
| Long-Term Debt | — | $0.00 -100.0% |
$195.8K -1.0% |
$197.8K | — |
| Stockholders Equity | -$3.38M -63.1% |
-$2.07M +18.1% |
-$2.53M -2901.1% |
-$84.2K -147.4% |
$177.6K |
| Operating Income | -$22.76M -567.8% |
-$3.41M -4253.1% |
-$78.3K +52.6% |
-$165.1K | — |
| Gross Profit | $1.66M -28.3% |
$2.31M +5382.6% |
$42.2K -78.7% |
$198.0K | — |
| Shares Outstanding | 956.99M +24.2% |
770.83M +185.8% |
269.75M | — | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $507.8K | -14.8% | +13.9% |
| Net Income | September 30, 2025 | -$80.6K | +79.6% | +54.8% |
| Diluted EPS | September 30, 2025 | $0.00 | — | — |
| Total Assets | September 30, 2025 | $1.17M | -93.3% | +1.5% |
| Cash and Equivalents | September 30, 2024 | $70.1K | — | +22.1% |
| Long-Term Debt | September 30, 2023 | $0.00 | — | -100.0% |
| Stockholders Equity | September 30, 2025 | -$3.65M | -126.9% | +0.2% |
| Operating Income | September 30, 2025 | -$8.5K | +97.4% | +92.1% |
| Gross Profit | September 30, 2025 | $426.4K | -11.5% | +21.0% |
| Shares Outstanding | September 30, 2025 | 961.99M | +0.6% | +0.1% |
- BIOREGENX, INC. reported Total Revenue of $2.34 million for fiscal year 2024.
- BIOREGENX, INC. showed a decrease of -31.4% in Total Revenue compared to the prior fiscal year.
- BIOREGENX, INC. reported Net Income of -$23.05 million for fiscal year 2024.
- BIOREGENX, INC. showed a decrease of -540.4% in Net Income compared to the prior fiscal year.
- BIOREGENX, INC. reported Diluted EPS of $0.02 per share (loss) for fiscal year 2024.
- BIOREGENX, INC. showed a decrease of -100.0% in Diluted EPS compared to the prior fiscal year.
- BIOREGENX, INC. reported Total Assets of $508.5 thousand for fiscal year 2024.
- BIOREGENX, INC. showed a decrease of -41.3% in Total Assets compared to the prior fiscal year.
- BIOREGENX, INC. reported Cash and Equivalents of $58.4 thousand for fiscal year 2024.
- BIOREGENX, INC. showed a decrease of -53.4% in Cash and Equivalents compared to the prior fiscal year.
- BIOREGENX, INC. reported Long-Term Debt of $0.00 for fiscal year 2023.
- BIOREGENX, INC. showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- BIOREGENX, INC. reported Stockholders Equity of -$3.38 million for fiscal year 2024.
- BIOREGENX, INC. showed a decrease of -63.1% in Stockholders Equity compared to the prior fiscal year.
- BIOREGENX, INC. reported Operating Income of -$22.76 million for fiscal year 2024.
- BIOREGENX, INC. showed a decrease of -567.8% in Operating Income compared to the prior fiscal year.
- BIOREGENX, INC. reported Gross Profit of $1.66 million for fiscal year 2024.
- BIOREGENX, INC. showed a decrease of -28.3% in Gross Profit compared to the prior fiscal year.
- BIOREGENX, INC. reported Shares Outstanding of 956.99 million shares for fiscal year 2024.
- BIOREGENX, INC. showed an increase of +24.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: